However, in one study, combining anti-IL1β antibodies with PD-1 blockade halted tumor progression altogether (Kaplanov et al., 2019b), illustrating that IL1β blockade could facilitate checkpoint inhibition.Clinical data supporting IL1β inhibition in TNBC and other solid tumor malignancies. Here, IL1B is linked to neoplasm.